Ozdogan, SelcukYaltirik, Cumhur KaanYilmaz, Seda GulecAkdeniz, Fatma TubaSumerkent, KadirDuzkalir, Ali HalukTure, Ugur2024-03-132024-03-1320200250-70051791-7530https://doi.org/10.21873/anticanres.14308https://hdl.handle.net/20.500.12662/3795Background/Aim: The aim of our study was to examine miRNA-221 as a candidate biomarker to define prognosis and/or classification for glial tumors. Materials and Methods: This study included 39 patients who underwent glial tumor surgery and 40 healthy individuals as the control group. miRNA expression levels were determined by real-time polymerase chain reaction (RT-PCR). Receiver operating characteristic curve analysis was used for analyzing the predictive ability of miRNA-221. Results: The levels of miRNA-221 expression were determined by comparing the Delta CT values of miRNAs and the internal control. When the expression levels of miRNA-221 were compared according to the Delta CT method, miRNA-221 was found to be significantly increased in the patient group compared to the control group (p<0.0001). Conclusion: Increased expression levels of miRNA-221 could be a biomarker for glial tumors.eninfo:eu-repo/semantics/openAccessGlial tumorsglioblastomamicroRNAmiRNA-221biomarkerArticle10.21873/anticanres.143082-s2.0-850859098243270632487621Q2326540WOS:000538104800027Q4